Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab as Adjunctive Therapy to Vitrectomy for PDR-DME
NCT04464694Phase 4Unknown
- Sponsor
- Xinhua Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), sponsored by Xinhua Hospital. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04464694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464694.